Month: August 2022

DNO Reports Strong Second Quarter Results, Ups Tawke License Guidance

Written by Customer Service on August 11, 2022. Posted in Earnings Releases And Operating Results.

Oslo, 11 August 2022 – DNO ASA, the Norwegian oil and gas operator, today reported strong second quarter operational and financial results powered by high oil and gas prices and by solid production in its operated flagship Kurdistan Tawke license. Spurred by quarterly revenue of USD 361 million and free cash flow of USD 167 million, the Company reduced debt and exited the quarter in a positive net cash position for the first time since 2018. “DNO is committed to put its capital to work in its core competency and capture new opportunities created as peers and even some of the largest European companies scale back spending and focus instead on harvesting,” said Executive Chairman Bijan Mossavar-Rahmani. “We believe in the oil and gas business and in our responsibility to all stakeholders, including host governments who want to capitalize...

Hexatronic Group AB (publ) Interim report January – June 2022

Written by Customer Service on August 11, 2022. Posted in Earnings Releases And Operating Results.

Hexatronic Group AB (publ)Interim report January – June 2022 Events during the quarterHexatronic executes share split, whereupon each share is divided into five shares (share split 5:1) of the same series.Events since the end of the quarterHexatronic signs a 3-year strategic partner agreement with Open Fiber USA, to a value of more than MUSD 40.Comments from the CEOContinued strong performance! The strong start to the year intensified during the second quarter. We achieved sales growth of 112 percent compared with the same quarter last year, of which 60 percent was organic growth. Profitability (EBITA) increased 174 percent equating to a margin of 16,8 percent, which exceeds our target of at least 12 percent by a good margin. The increase in profitability is primarily a result of strong performances in the USA and UK, a good product...

Valneva Reports H1 2022 Results and Provides Corporate Updates

Written by Customer Service on August 11, 2022. Posted in Earnings Releases And Operating Results.

Excellent progress on late-stage clinical programs Lyme Disease Vaccine Candidate VLA15Phase 3 study initiated in August 20221 Further positive Phase 2 results reported, including first pediatric data2Single-Shot Chikungunya Vaccine Candidate VLA1553Initiation of rolling submission for Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) imminent Final positive pivotal Phase 3 results reported3 Final positive lot-to-lot consistency Phase 3 results reported4Four marketing authorizations granted for inactivated COVID-19 vaccineFirst Standard Marketing Authorization granted in Europe by the European Medicines Agency (EMA)5 Conditional Marketing Authorization granted in the United Kingdom (UK) by the Medicines and Healthcare products Regulatory Agency (MHRA)6 and Emergency Use Authorizations granted...

ForFarmers N.V.: ForFarmers 2022 first-half results

Written by Customer Service on August 11, 2022. Posted in Earnings Releases And Operating Results.

Lochem, 11 August 2022 ForFarmers 2022 first-half results Increase underlying EBITDA due to positive results in countries outside of the Netherlands Financial highlights for first-half of 20221:Total Feed2 volume: -7.4% to 4.5 million tonnes; due to like-for-like decline in all clusters of which compound feed: -7.9% to 3.2 million tonnes; decline in all clusters Gross profit: +18.3% to €257.3 million; higher raw material and energy prices largely passed on in Q2; 1H 2021 depressed by German incident Underlying EBITDA: +5.6% to €43.1 million; higher gross profit and efficiency measures Underlying net profit3: -4.5% to €17.1 million; mainly due to increased interest expenses and higher effective tax rate Working capital: ...

Six-month interim report (Q2) 2022

Written by Customer Service on August 11, 2022. Posted in Public Companies.

ALK reports Q2 revenue up 17%, EBITDA up 123%, and full-year outlook upgraded (unaudited) Performance in Q2 was better than expected with double-digit growth in all regions and ALK reported its best-ever Q2 results. Total revenue was up 17% led by sales growth from tablets and Jext®. In Europe, ALK’s largest region, sales were up 14% and bounced back strongly after the COVID-led headwinds of Q1. Operating profit (EBITDA) increased 123% on sales growth and improved gross margin. Based on the strong sales momentum, ALK has upgraded its financial outlook for 2022. Q2 2022 financial highlightsTotal revenue was up 17% in local currencies to DKK 1,045 million (868). Currencies had a positive effect of 3 percentage points, resulting in reported growth of 20%. Revenue for the first six months was up 14% in local currencies (16% reported growth)...

CinCor Pharma Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Written by Customer Service on August 11, 2022. Posted in Public Companies.

WALTHAM, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, baxdrostat, for the treatment of hypertension and other cardio-renal diseases, today announced the pricing of its underwritten public offering, which was upsized to an aggregate of 7,500,000 shares of common stock and pre-funded warrants to purchase common stock, from the original offering size of 6,000,000 shares and pre-funded warrants. The offering consists of 4,900,000 shares of its common stock, and, to certain investors, pre-funded warrants to purchase 2,600,000 shares of its common stock at an exercise price of $0.00001. The public offering price of each share of common stock is $30.00 and the public offering price of each pre-funded...

FY22 Full Year Results Briefing

Written by Customer Service on August 11, 2022. Posted in Public Companies.

BRISBANE, Australia, Aug. 11, 2022 (GLOBE NEWSWIRE) — Allkem Limited (ASX|TSX: AKE) (“Allkem” or “the Company”) will release its Full Year Results on Thursday, 25 August 2022. Managing Director and CEO, Mr. Martín Pérez de Solay and CFO, Neil Kaplan will conduct a live webcast briefing at 09:00 am AEST (Brisbane, Sydney, Melbourne) on the same day. To pre-register your details and join the webcast briefing, please follow the link on the homepage of Allkem’s website, www.allkem.co. Written questions may be submitted via the webcast and playback of the briefing and Q&A session will also be available on the company’s website. This release was authorised by Mr Martin Perez de Solay, CEO and Managing Director of Allkem Limited. Allkem Limited ABN 31 112 589 910 Level 35, 71 Eagle StBrisbane, QLD 4000 Investor Relations &...

Canadian Premium Sand Inc. Announces Increase to Previously Announced Equity Financing

Written by Customer Service on August 11, 2022. Posted in Public Companies.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA CALGARY, Alberta, Aug. 10, 2022 (GLOBE NEWSWIRE) — Canadian Premium Sand Inc. (“CPS” or the “Company”) (TSXV: CPS) is pleased to announce that due to strong demand it has agreed with Peters & Co. Limited and Fort Capital Partners (together, the “Agents”) to increase the size of the previously announced best efforts private placement financing (the “Brokered Offering”). CPS will now issue up to 28,500,000 units of the Company (each, a “Unit”) at a price of $0.30 per Unit (the “Offering Price”) for gross proceeds to the Company of up to $8,550,000 pursuant to the Brokered Offering. In conjunction with the Brokered Offering, the Corporation will complete, on a private placement basis, a non-brokered offering of up to 3,600,000...

Belite Bio Reports First Half 2022 Operational Highlights and Financial Results

Written by Customer Service on August 11, 2022. Posted in Earnings Releases And Operating Results.

– LBS-008 (aka Tinlarebant) is Belite Bio’s orally administered tablet for the treatment of Stargardt disease (STGD1) and Dry AMD – A 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STGD1 are ongoing – The Phase 3, Multicenter, Randomized, Double Masked, Placebo Controlled Study to Evaluate the Safety and Efficacy of TinlaRebant in the Treatment of StArGardt Disease in AdOlesceNt Subjects (DRAGON) trial has commenced in the U.S., the United Kingdom, Germany, Belgium, Switzerland, Hong Kong, Taiwan, and Australia, and several patients have been enrolled – LBS-008, Belite Bio’s lead asset, has been granted fast track designation, rare pediatric disease designation (RPD) in the U.S., and orphan drug designation (ODD) in the U.S. and Europe for STGD1 – Conference...

Avricore Grants Options

Written by Customer Service on August 11, 2022. Posted in Public Companies.

VANCOUVER, British Columbia, Aug. 10, 2022 (GLOBE NEWSWIRE) — AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “AVCR”) is pleased to announce that the Company’s board of directors has approved the granting of stock options (the “Options”) exercisable for a total of 2,725,000 common shares to its directors, officers, and consultants at an exercise price of CAD$0.15 per common share. All Options were granted pursuant to the Company’s stock option plan and are subject to the terms of the applicable grant agreements and the requirements of the TSX Venture Exchange. The options are subject to a 1-year vesting period, with ¼ of the options vesting 3 months after the date of the grant and the remaining options vesting on a quarterly basis thereafter. The options expire 5 years from the date of the grant, subject to the...

Month: August 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals